Vial Dermatology CRO logo

Vial Welcomes Amy Del Medico as Vice President of Ophthalmology: Advancing Clinical Trial Management Services

Elevating Clinical Trials with Visionary Leadership

Key Takeaways

  • Vial, a global tech-forward Contract Research Organization (CRO), proudly announces the appointment of Amy Del Medico as Vice President of Ophthalmology.
  • Amy’s distinguished career spanning over two decades includes pivotal roles in strategic planning for U.S. and global clinical trials, making her a respected figure in the realm of ophthalmology.
  • With an innovative approach and integration of technology, Vial is set to redefine clinical trial execution, aiming for efficiency and cost-effectiveness.

SAN FRANCISCO, Aug. 10, 2023 /PRNewswire/ – Vial, a trailblazing global Contract Research Organization (CRO) at the forefront of modernizing clinical trial management services, has marked a significant step in its journey with the announcement of Amy Del Medico as their Vice President of Ophthalmology. Amy brings to Vial a wealth of experience from over two decades of strategic planning for U.S. and global clinical trials, with a focus on ophthalmology.

A Career Path of Distinction

Amy’s career path is marked by pivotal roles within the pharmaceutical and biotechnology sectors. Prior to joining Vial, her journey included notable positions at IQVIA, where she played a crucial role in shaping therapeutic strategies for ophthalmology and neurology clinical studies. Her adeptness in collaborating with diverse stakeholders, ranging from small biotech firms to major pharmaceutical companies, across all phases of study, has solidified her reputation as a respected figure in the realm of retina and anterior segment trials. With an unparalleled understanding of research phases, encompassing observational and device studies, Amy has made her mark in ophthalmology, spanning from rare diseases to cutting-edge cell and gene therapies.

Amy’s dedication and passion for advancing clinical trials shine through in her own words: “Vial’s vision of harnessing technology to revolutionize the clinical trial landscape deeply resonates with me. The industry’s transformation, driven by the challenges of the COVID era, has paved the way for transformative change. I am excited to contribute to a company that is leading the charge in conducting trials with greater efficiency and effectiveness.”

Pioneering Technology-Driven Clinical Trials

Vial’s approach to clinical trial execution stands out with its incorporation of forward-thinking technology. The company’s innovative platform seamlessly integrates eSource, Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO), creating a cohesive system that streamlines processes from site initiation to data collection and database lock. This tech-driven approach not only enhances efficiency but also paves the way for more accurate and timely data analysis.

Simon Burns, CEO and Co-Founder of Vial, acknowledges the significance of Amy’s addition: “We are thrilled to welcome Amy as our Vice President of Ophthalmology at Vial. Her extensive experience and unmatched expertise in ophthalmology clinical trials align perfectly with our mission to redefine trial conduct. With Amy on board, we are well-equipped to drive innovation and deliver groundbreaking therapies that benefit both sponsors and patients on a global scale.”

The Vial Advantage: Redefining Clinical Trials

Vial’s commitment to transforming clinical trials is deeply rooted in its innovative use of technology. The company’s technology platform powers trials from start to finish, facilitating seamless communication between all stakeholders involved. The integration of modern, intuitive eSource, EDC, and ePRO into one connected system streamlines site processes, reducing administrative burden and enabling substantial efficiencies.

With an impressive presence across multiple Therapeutic Areas, including Dermatology, Ophthalmology, Oncology, Gastroenterology, Neurology, Cardiology, Medical Devices, Rare Diseases, and Digital Therapeutics, Vial is poised to drive change and elevate clinical trial management in diverse fields.

About Vial

Vial stands as a beacon of innovation in the realm of clinical trial management. Powered by technology, Vial promises faster and more efficient trial execution at a reduced cost. The company’s comprehensive platform harmonizes site startup, data collection, and database lock, utilizing modern eSource, EDC, and ePRO solutions. Operating from its base in San Francisco, California, Vial is a team of over 100 dedicated professionals working to redefine how clinical trials are conducted.

Shaping the Future of Clinical Trials

Amy Del Medico’s appointment as Vice President of Ophthalmology at Vial highlights the company’s commitment to leveraging technology and expertise to reshape clinical trials. With a strong foundation and visionary leadership, Vial is set to lead the way in efficient, effective, and transformative clinical trial management.

Nature Coatings: Pioneering Bio-Based Solutions with $2.45 Million Funding Boost

Fenwick’s “Closing Time” Podcast: Demystifying the Journey of Healthcare Startups